Overview:
A yet2 client is seeking emerging biomarkers for a wide variety of neurological diseases, including but not limited to neurodegenerative (e.g., Alzheimer’s, Parkinson’s, Huntington’s), autoimmune (e.g., Multiple Sclerosis), neuropsychiatric (e.g., depression, generalized anxiety disorder), neuromuscular (e.g., Duchenne Muscular Dystrophy) and acquired/traumatic disorders (e.g., traumatic brain injury [TBI]) in order to support their current products as well as future development. Solutions may support a variety of diagnostic/regulatory uses cases, i.e., research use only (RUO), in-vitro diagnostics (IVD), and clinical trial assay (CTA).
Constraints:
Biomarkers will ideally:
- Have human data available – however, biomarkers with only cell culture or animal data are also of interest
- Be protein-based – however, other markers, including but not limited to nucleic acids, lipids, and metabolites are also of interest
- Utilize routine sample materials (e.g., CSF, serum, plasma) or less-invasive samples (e.g., saliva, urine, sweat)
Desired outcome of the solution:
Collaboration with organizations to further validate biomarkers for commercial use.
Related TechNeeds:
Seeking: Ostomy and Urinary Retention Sensors
Seeking: Advanced Materials and Sensors for the Detection of Pilot Stress and Fatigue
Seeking: Remote Monitoring for Pediatric Epilepsy
Seeking: Wearables to Monitor Dermal Bioindicators
Image by Jesse Orico on Unsplash
